| AKI | acute kidney injury |
| AKIN | acute kidney injury network |
| ATN | acute tubular necrosis |
| CF | concentration in the filtrate |
| CP | concentration in plasma water |
| CPFA | coupled plasma filtration adsorption |
| CRRT | Continuous Renal Replacement Therapy |
| CVVH | continuous veno-venous hemofiltration |
| CVVHDF | continuous veno-venous hemodiafiltration |
| DFO | deferoxamine |
| FD | protease factor D |
| FDA | Food and Drug Administration |
| GalNAc | N-acetylgalactosamine |
| GPI | glycosyl phosphatidylinositol |
| HD | hemodialysis |
| KDIGO | Kidney Disease Improving Global Outcome |
| MAC | membrane attack complex |
| LDH | lactate dehydrogenase |
| LPS | lipopolysaccharide |
| Chronic Kidney Disease | chronic kidney disease |
| HB | hemoglobin |
| NF-κB | Nuclear Factor kappa B |
| MN | Membranous Nephropathy |
| MW | molecular weights |
| NO | nitric oxide |
| Nrf2 | nuclear factor erythroid-2-related factor 2 |
| HO-1 | Heme oxygenase 1 |
| PIG-A | phosphatidylinositol glycan class A |
| PNH | Paroxysmal nocturnal hemoglobinuria |
| PTECs | proximal tubular epithelial cells |
| RIFLE | risk, injury, failure, loss, end-stage kidney disease |
| ROS | reactive oxygen species |
| NaHCO3 | sodium bicarbonate |
| RRT | renal replacement therapy |
| THP | Tamm Horsfall protein |